19. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: Dcg(Me)-2Nal-Atmp(Me), Dcg-2Nal-Ama, Dcg-2Nal-Apa, Dcg-2Nal-Atmp, Dcg-2Nal-Atpc, Dcg-2Nal-Atpm, Dcg-2Nal-mA2Bz, Dcg-2Nal-mA2Bz(Dcg), Dcg-2Nal-mA2Bz(Gun), Dcg-2Nal-mABz, Dcg-2Nal-Tpac, Dcg-Apa-Atmp, Dcg-BtA-Atmp, Dcg-D2Nal-Apa, Dcg-D2Nal-Atmp, Dcg-D2Nal-Atmp, Dcg-F5f-Atmp, Dcg-Igl-Apa, Dcg-Igl-APa(anisyl), Dcg-Igl-Aptp, Dcg-Igl-Aqu, Dcg-Igl-Atmp, and Dcg-Trp-Atmp.

20. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 19 to the animal.

21. (New) The method of Claim 20, wherein the animal is a human.

22. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: F5c-2Nal-3Ampy, F5c-2Nal-Ampz, F5c-2Nal-Aqd, F5c-2Nal-Atmp, F5c-2Nal-Dmab, F5c-2Nal-Dmp, F5c-2Nal-Tpac, F5c-3Pal-Atmp, F5c-Arg, F5c-BtA-Atmp, F5c-Cys(Meb)-Atmp, F5c-Iqa-Atmp, F5c-MC2Y-Atmp, F5c-MC2Y-Atmp, F5c-OC2Y-Dmab, F5c-OC2Y-Mapp, F5c-OC2Y-Matp, F5c-OCIY-Matp, F5c-Oic-Atmp, F5c-PaF(Mes)-Atmp, F5c-PFF-Dmab, F5c-Tic-Atmp, F5c-tLeu-Atmp, F5c-Tyr(Bzl)-Atmp, and F5c-Tyr-Atmp.

23. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 22 to the animal.

24. (New) The method of Claim 23, wherein the animal is a human.

25. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: 2Nap-PaF(Dcg), 2Nap-PaF(Mcg), Ac-OC2Y-Arg, Ac-PaF(Mcg)-Arg, Ac-PaF(Sin)-Arg, Ac-PdF-Arg, Cca-hPhe-Arg, Cin-hPhe-Arg, Dca-hPhe-Arg, Dpa-PFF-Arg, F5bz-F5F-Arg, Gun-2Nal-Arg, Gun-D2Nal-Apa, Gun-Eac-D2Nal-PgF, Gun-Ica-Arg, Mca-hPhe-Arg, Mcg-APa-mABz, Mse-Pac-BtA-Atmp, Mse-Pac-Igl-Atmp, Oic-Arg, Pac-hPhe-Arg, Pcc-hPhe-Arg, Ppa-hPhe-Arg, Ppa-PFF-Arg, Pya-hPhe-Arg, Pya-pABz-2Nal, Saa-hPhe-Arg, Seb-Pac-Igl-Atmp, Sin-F5F-3Pal, Ste-2-Nal-Arg, Sul-2Nal-Atmp, and Tfmc-pAPa-Asp-Atmp.

26. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 25 to the animal.

27. (New) The method of Claim 26, wherein the animal is a human.

28. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: Dcg-(D,L)Atc-Arg, Dcg-2Nal-3Pal, Dcg-2Nal-APa-Sud, Dcg-2Nal-Aqu, Dcg-2Nal-Arg, Dcg-2Nal-Asp, Dcg-2Nal-Asp(Aqu), Dcg-2Nal-Asp-(R,S)Aqu, Dcg-2Nal-Asp-(R,S)Aqu, Dcg-2Nal-Asp-Atmp, Dcg-2Nal-Glu-Atmp, Dcg-2Nal-pABz, Dcg-2Nal-PgF, Dcg-Ac6c-Arg, Dcg-Aic-Arg, Dcg-Apa-Arg, Dcg-Apa-mABz, Dcg-Asp-Aqu, Dcg-Atpc-Arg, Dcg-BtA-Arg, Dcg-D-2Nal-Arg, Dcg-D2Nal-mABz, Dcg-F5F-Arg, Dcg-hPhe-Arg, Dcg-Igl-Arg, Dcg-Ile-Arg, Dcg-p-Amb-Arg, Dcg-pAPa-Asp-Atmp, and Dcg-Trx-Arg.

29. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 28 to the animal.

30. (New) The method of Claim 29, wherein the animal is a human.

31. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: F5c-(N-Dmb)-Tyr(Bzl)-OMe, F5c-2Nal-Arg, F5c-2Nal-Arg-NH_2, F5c-2Nal-Cys(SO_3H)-Atmp, F5c-3,4F2F-Arg, F5c-3-Pal-Arg, F5c-Ana-Arg, F5c-APb-Arg, F5c-Bip-Arg, F5c-DhPhe-Arg, F5c-Dpr(Fbz)-Arg, F5c-Dpr(Paa)-Arg, F5c-F5F-Arg, F5c-hPhe-Arg, F5c-Lys(F5bz)-Arg, F5c-Lys{$(CH_3)_3$}-Arg, F5c-mABz-2Nal-Ampz, F5c-m-APa-Arg, F5c-MBC-Arg, F5c-MFF-Arg, F5c-NMF-Arg, F5c-OBS-Arg, F5c-OBT-Arg, F5c-OC2Y-Arg, F5c-Oic-Arg, F5c-pABz-2Nal, F5c-p-ABz-Arg, F5c-Pac-Arg, F5c-PaF(Ppa)-Arg, F5c-p-Amb-Arg, F5c-p-APa-Arg, F5c-pAPa-Asp-Atmp, F5c-PCF-Arg, F5c-PFF-Arg-NH_2, F5c-Phe-Arg, F5c-PNF-Arg, F5c-Thi-Arg, F5c-Tic-Arg, F5c-Trp-Arg, and F5c-Tyr-Arg.

32. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 31 to the animal.

33. (New) The method of Claim 32, wherein the animal is a human.

34. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: Aaa-DIgl-hPhe-Arg, Aaa-DPhe-hPhe-Arg, Aaa-DTic-hPhe-Arg, Aaa-Pac-hPhe-Arg, Ac-PaF(Dcg)-p-ABz-Arg, Ac-PaF(Mcg)-p-ABz-Arg, Dcg-2Nal-Atpc-Arg, Dcg-Gly-Cmp-Arg, Dcg-Gly-Oic-Arg, DIgl-Oic-Arg, F5c-DArg-2Nal-Arg-Matp, F5c-DArg-hPhe-Arg, F5c-Gly-mABz-2Nal, F5c-pABz-2Nal-Arg, F5c-p-Amb-APa-Arg, Inp-Dpr(Dcg-2Nal), and Pya-Gly-mABz-Aqd.

35. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 34 to the animal.

36. (New) The method of Claim 35, wherein the animal is a human.

37. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: Aaa-Ser-Pac-hPhe-Arg, Ac-DArg-Arg-Aud-DF5F-Oic-Arg, Ac-Pac-Gly-m-Abz-2Nal-Arg, Ac-Pac-Gly-mABz-Nal, Arg-DNMF-DTrp-Phe-DTrp-Leu, Arg-Eac-DIgl-Ana-Arg, Ava-Igl-Ser-DF5F-Oic-Arg, DArg-Arg-Aud-DIgl-PFF-Arg, D-Arg-Arg-Aud-PaF(F5c)-Arg, Dcg-DIgl-Oic-Arg, Dcg-Pac-Gly-mABz-2Nal, Dcg-Pac-Gly-m-ABz-2-Nal-Arg, DNMF-DTrp-Phe-DTrp-Leu$\Psi(CH_2NH)$Leu-NH_2, F5c-DArg-Arg-Aud-DIgl-hPhe-Arg, F5c-DArg-Arg-Aud-DIgl-PFF-Arg, F5c-DArg-Arg-Aud-DTic-hPhe-Arg, F5c-DArg-Arg-Aud-DTic-Oic-Arg, F5c-DArg-Arg-Aud-Pac-2Nal-Arg, F5c-DArg-Aud-OC2Y-Gly-Atmp, F5c-DArg-Eac-2Nal-Arg, F5c-DArg-Eac-hPhe-Arg, F5c-DArg-PFF-Arg-PFF-NH_2, F5c-Gly-mABz-2Nal-Arg, F5c-Lys-Ser-DF5F-Oic-Arg, Gly-Igl-Ser-DIgl-Oic-Arg, Gun-Eac-DIgl-Oic-Arg, Igl-Ser-DIgl-Oic-Arg, Mcg-Pac-Gly-m-ABz-2-Nal-Arg, and Ser-DIgl-Oic-Arg.

38. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 37 to the animal.

39. (New) The method of Claim 38, wherein the animal is a human.

40. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: Aca-c[DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Nig-Oic-Arg], α-DDD-(c[Lys-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DF5F-Oic-Arg])$_2$, c[Add-DArg-F5F-Arg], c[Arg-DNMF-DTrp-Phe-DTrp-Leu], c[Ava-Igl-Ser-DF5F-Oic-Arg], c[Bala-DArg-Arg-Eac-Ser-DF5F-Oic-Arg], c[DArg-Arg-Add-DF5F-Oic-Arg], c[DArg-ArgAdd-DIgl-PFF-Arg], c[DArg-Arg-Add-Ser-DF5F-Oic-Arg], c[DArg-Arg-Add-Ser-DIgI-PFF-Arg], c[DArg-Arg-Aud-

DF5F-Oic-Arg], c[DArg-Arg-Aud-Dlgl-PFF-Arg], c[DArg-Arg-Aud-Ser-DF5F-Oic-Arg], c[DArg-Arg-Ava-Ser-DF5F-Oic-Arg], c[DArg-Arg-Ava-Ser-DIgl-PFF-Arg], c[DArg-Arg-Eac-DF5F-Oic-Arg], c[DArg-Arg-Eac-DIgI-PFF-Arg], c[DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg], c[DArg-Arg-Eac-Ser-DF5F-Oic-Arg], c[DArg-Arg-Pro-Hyp-Gly-Igl-Ser-Dlgl-Oic-Arg], c[DNiK-Arg-Eac-Ser-DF5F-Oic-Arg], c[DNiK-PzO-Eac-Ser-DF5F-Oic-Arg], and c[Suc-DArg-Arg-Eac-Ser-DIgI-PaF-Arg].

41. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 40 to the animal.

42. (New) The method of Claim 41, wherein the animal is a human.

43. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: $(F5c\text{-}DArg\text{-}Igl\text{-}Arg)_2$-DDA, $Btac\text{-}(2Nal\text{-}Atmp)_2$, $Btac\text{-}(2Nal\text{-}Atmp)_3$, $DDD\text{-}(2Nal\text{-}Asp\text{-}Atmp)_2$, $DDD\text{-}(3Pal\text{-}Nal\text{-}Cyh)_2$, $DDD\text{-}(Arg\text{-}2Nal\text{-}Atmp)_2$, $DDD\text{-}(BtA\text{-}Atmp)_2$, $DDD\text{-}(DArg\text{-}2Nal\text{-}Atmp)_2$, $DDD\text{-}(DArg\text{-}OC2Y\text{-}Dmab)_2$, $DDD\text{-}(His\text{-}1Nal\text{-}Atmp)_2$, $DDD\text{-}(Pac\text{-}2Nal\text{-}Ampz)_2$, $DDD\text{-}(Pac\text{-}2Nal\text{-}Api)_2$, $DDD\text{-}(Pac\text{-}2\text{-}Nal\text{-}Dmp)_2$, $DDD\text{-}(Pac\text{-}INal\text{-}Atmp)_2$, $DDD\text{-}[Arg(Tos)\text{-}2Nal\text{-}Atmp]_2$, $DDD\text{-}[DArg\text{-}2Nal\text{-}Atmp]_2$, $Dtp\text{-}(2Nal\text{-}Atmp)_2$, $DTP\text{-}(DArg\text{-}Igl\text{-}Arg\text{-}Matp)_2$, $EDTA\text{-}(OC2Y\text{-}Atmp)_4$, $HDD\text{-}(DArg\text{-}Igl\text{-}Arg\text{-}Matp)_2$, HOOC-DDD-Pac-2Nal-Ampz, $SBEC\text{-}(DArg\text{-}2Nal\text{-}Arg\text{-}Matp)_2$, ζ-$SUB\text{-}(ApC\text{-}F5F\text{-}Arg)_2$, $TDIM\text{-}(2Nal\text{-}Atmp)_2$, $TDIM\text{-}(2Nal\text{-}Atmp)_2$, $TDIM\text{-}(2Nal\text{-}Atmp)_2$, $TDIM\text{-}(2Nal\text{-}DMM)_2$, $TDIM\text{-}(BtA\text{-}Atmp)_2$, $TDIM\text{-}(Igl\text{-}Atmp)_2$, $TDIM\text{-}(Igl\text{-}Atmp)_2$, and TDIM-BtA-Atmp.

44. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 43 to the animal.

45. (New) The method of Claim 44, wherein the animal is a human.

46. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: α-$DDD\text{-}(ApC\text{-}F5F\text{-}Arg)_2$, α-$DDD\text{-}(Lys\text{-}DArg\text{-}2Nal\text{-}Atmp)_2$, $DDD\text{-}(DArg\text{-}2Nal\text{-}Arg)_2$, $DDD\text{-}(DArg\text{-}2Nal\text{-}Arg\text{-}Dmab)_2$, $DDD\text{-}(DArg\text{-}2Nal\text{-}Arg\text{-}NH_2)_2$, $DDD\text{-}(DArg\text{-}BtA\text{-}Arg\text{-}Matp)_2$, $DDD\text{-}(DArg\text{-}F5F\text{-}Arg\text{-}Dmab)_2$, $DDD\text{-}(DArg\text{-}F5F\text{-}Arg\text{-}Dpea)_2$, $DDD\text{-}(DArg\text{-}F5F\text{-}Arg\text{-}Matp)_2$, $DDD\text{-}(DArg\text{-}F5F\text{-}DArg)_2$, $DDD\text{-}(DArg\text{-}F5F\text{-}DArg\text{-}NH_2)_2$, $DDD\text{-}(DArg\text{-}hPhe\text{-}Arg)_2$, $DDD\text{-}(DArg\text{-}hPhe\text{-}Arg\text{-}NH_2)_2$, $DDD\text{-}(DArg\text{-}Igl\text{-}Mapp)_2$, $DDD\text{-}(DArg\text{-}OBS\text{-}Arg)_2$, $DDD\text{-}(DArg\text{-}OC2Y\text{-}Arg)_2$, $DDD\text{-}(DArg\text{-}PFF\text{-}Arg)_2$, DDD-(DArg-PFF-Arg-

Dpea)$_2$, DDD-(DArg-PFF-Arg-Dpma)$_2$, DDD(DArg-PFF-Arg-Dpma)-DArg-PFF-Arg-NH_2, DDD-(DArg-PFF-Arg-NH_2)$_2$, DDD-(DIgl-hPhe-Arg)$_2$, DDD-(DNiK-F5F-Arg)$_2$, DDD-(DPhe-hPhe-Arg)$_2$, DDD-(DPzK-F5F-Arg)$_2$, DDD-(DPzO-F5F-Arg)$_2$, DDD-(pABz-2Nal-Arg)$_2$, DDD-(pABz-2Nal-Arg-NH_2)$_2$, DDD-(p-ABz-hPhe-Arg)$_2$, DDD-(Pac-2Nal-Arg)$_2$, DDD-(Pac-2Nal-Arg-NH_2)$_2$, DDD-(Pac-2Nal-Atmp)$_2$, DDD-(Pac-2Nal-DArg-NH_2)$_2$, DDD-(Pac-hPhe-Arg)$_2$, DDD-(Pac-Igl-Atmp)$_2$, and DDD-(PzO-F5F-Arg)$_2$.

47. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 46 to the animal.

48. (New) The method of Claim 47, wherein the animal is a human.

49. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: DDD-(Arg-DIgl-Oic-Arg)$_2$, DDD-(Arg-DIgl-Oic-Arg-OMe)$_2$, DDD-(DArg-Arg-Aud-DF5F-Oic-Arg)$_2$, DDD-(DArg-Arg-Aud-DIgl-hPhe-Arg)$_2$, DDD-(DArg-Arg-Aud-DIgl-PFF-Arg)$_2$, DDD-(DArg-Arg-Aud-DTic-hPhe-Arg)$_2$, DDD-(DArg-Arg-Aud-DTic-Oic-Arg)$_2$, DDD-(DArg-Arg-Aud-Pac-2Nal-Arg)$_2$, DDD-(DArg-Arg-Aud-Pac-2Nal-Atmp)$_2$, DDD-(DArg-Arg-Aud-Pac-2Nal-DArg-NH_2)$_2$, DDD-(DArg-Arg-Aud-Pac-hPhe-Arg)$_2$, DDD-(DArg-Arg-Aud-Pac-PaF(Fbz)-Arg)$_2$, DDD-(DArg-Arg-Aud-PaF(F5c)-Arg)$_2$, DDD-(DArg-F5F-Arg-PaF-NH_2)$_2$, DDD-(DArg-PFF-Arg-PFF-NH_2)$_2$, DDD-(Eac-Arg-DIgl-Oic-Arg)$_2$, DDD-(Eac-Arg-DIgl-Oic-Arg)$_2$, DDD-(Eac-Arg-DIgl-Oic-Arg-OMe)$_2$, DDD-(Eac-Eac-Arg-DIgl-Oic-Arg)$_2$, DDD-(Lys-Pac-Gly-mABz-2Nal-NH_2)$_2$, and DDD-(Lys-Ser-DF5F-Oic-Arg)$_2$.

50. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 49 to the animal.

51. (New) The method of Claim 50, wherein the animal is a human.

52. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: α-DDD-(Lys-DNMF-DTrp-Phe-DTrp-LeuΨ(CH_2NH)Leu-NH_2)$_2$, α-DDD-(Lys-B9430-OMe), DDD-(DArg-Arg-Add-Ser-DIgl-Oic-Arg)$_2$, DDD-(DArg-Arg-Add-Ser-DIgl-PFF-Arg)$_2$, DDD-(DArg-Arg-Aud-Ser-DF5F-Oic-Arg)$_2$, DDD-(DArg-Arg-Aud-Ser-DIgl-Oic-Arg)$_2$, DDD-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)$_2$, DDD-(DArg-Arg-Eac-Ser-DF5F-Oic-Arg)$_2$, DDD-(DArg-Arg-Eac-Ser-DF5F-PFF-Arg)$_2$, DDD-(DArg-

Arg-Eac-Ser-DIgl-Oic-Arg)$_2$, DDD-(DArg-Arg-Eac-Ser-DIgl-PFF-Arg)$_2$, DDD-(DArg-Arg-Eac-Ser-DTic-Oic-Arg)$_2$, DDD-(DmK-DArg-Arg-Eac-Ser-DF5F-Oic-Arg)$_2$, DDD-(DNiK-Arg-Eac-Ser-DF5F-Oic-Arg)$_2$, DDD-(DNiK-PzO-Eac-Ser-DF5F-Oic-Arg)$_2$, and DDD-(DNMF-DTrp-Phe-DTrp-LeuΨ(CH_2NH)Leu-NH_2)$_2$.

53. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 52 to the animal.

54. (New) The method of Claim 53, wherein the animal is a human.

55. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: (DArg-Arg-Pro-HYP)$_2$-Dpr-Igl-Ser-DIgl-Oic-Arg, (Gun)$_2$-BApG-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, 33Dp-DArg-Arg-Aud-Ser-DF5F-Oic-Arg, Aaa-DArg-Arg-Aud-Ser-DF5F-Oic-Arg, Aaa-DArg-Arg-Eac-Ser-DF5F-Oic-Arg, Aaa-DArg-Arg-Pro-Hyp-Gly-(D,L)DMF-Ser-DTic-Oic-Arg, Aaa-DArg-Arg-Pro-Hyp-Gly-(D,L)DMF-Ser-DTic-Oic-Arg, Aca-DArg-Arg-Aud-Ser-DF5F-Oic-Arg, Aca-DArg-Arg-Eac-Ser-DF5F-Oic-Arg, Aca-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-(D,L)Igl-Oic-Arg, α-DDD-(Lys-DNMF-DTrp-Phe-DTrp-LeuΨ(CH_2NH)Leu-NH_2)$_2$, Arg-Pro-Lys-Pro-DTrp-Gln-DTrp-Phe-DTrp-LeuΨ(CH_2NH)Leu-NH_2, Arg-Pro-Pro-Gly-Phe-Thr-DTic-Oic-Arg, Arg-Pro-Pro-Gly-Phe-Thr-DTic-Oic-NH_2, BApG-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Nig-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-NMF-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-CpG-Ser-DCpG-CpG-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Nc7G-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-Eac-Eac-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-NH_2, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-PFF-Arg, DArg-Arg-Pro-Hyp-Gly-Phe-Ser-DCpG-CpG-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-CpG-DCpG-DArg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nc6G-Arg, DArg-Arg-Pro-Lys-Pro-DTrp-Gln-DTrp-Phe-DTrp-LeuΨ(CH_2NH)Leu-NH_2, DArg-Arg-Pro-MeP-Gly-CpG-Ser-DCpG-CpG-Arg, DArg-Pro-Lys-Pro-DTrp-Qln-DTrp-Phe-DTrp-LeuΨ(CH_2NH)Leu-NH_2, DArg-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Dhq-DArg-Arg-Pro-Hyp-Gly-CpG-Ser-DCpG-CpG-Arg, Dmac-DArg-Arg-Aud-Ser-DF5F-Oic-Arg, DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, DNiK-PzO-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, F5bz-DArg-Arg-Aud-Ser-DF5F-Oic-Arg, F5c-DArg-Arg-Add-Ser-DIgl-Oic-Arg, F5c-DArg-Arg-Aud-Ser-DF5F-Oic-Arg, F5c-DArg-Arg-Aud-Ser-DIgl-Oic-Arg, F5c-DArg-Arg-Eac-

Ser-DF5F-Oic-Arg, F5c-DArg-Arg-Eac-Ser-DF5F-PFF-Arg, F5c-DArg-Arg-Eac-Ser-DIgl-Oic-Arg, F5c-DArg-Arg-Eac-Ser-DTic-Oic-Arg, F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-PFF-Arg, F5c-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-PFF-Arg, F5pa-DArg-Arg-Aud-Ser-DF5F-Oic-Arg, Gun2-BApg-DArg-Arg-Eac-Ser-DF5F-Oic-Arg, Hyp-Gly-Igl-Ser-DIgI-Oic-Arg, Leu-DTrp-Phe-DTrp-DNMF-Eac_2-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, Leu-Leu-DTrp-Phe-DTrp-DNMF-Eac_2-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, Moti-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, and Moti-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg.

56. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 55 to the animal.

57. (New) The method of Claim 56, wherein the animal is a human.

58. (New) A compound or a pharmaceutically acceptable salt thereof represented by a formula selected from the group consisting of: α-DDD-(Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)$_2$, α-Sub-(Lys(εFlu)-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DDD-(DmK-PzO-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg)$_2$, DDD-(Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)$_2$, DTP-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)$_2$, EGS-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)$_2$, EGS-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)$_2$, εSUB-(Lys-DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)$_2$, SBEC-(DArg-Arg-Eac-Ser-DF5F-Nc7G-Arg)$_2$, Sub-(Arg-DNMF-DTrp-Phe-DTrp-Leu)-α-Lys-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, SUB-(DArg-Arg-Eac-Ser-DF5f-Nc7G-Arg)$_2$, SUIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg-NH_2)$_2$, TDIM-(DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg)$_2$, and TDIM-(DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DIgl-Oic-Arg)$_2$.

59. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering the compound or salt of Claim 58 to the animal.

60. (New) The method of Claim 59, wherein the animal is a human.

61. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

2,3,4,5,6-Pentafluorocinnamoyl — D-Arginine — Arginine — Proline — Trans-4-hydroxyproline — Glycine — α-2-Indanylglycine — Serine — D-α-2-Indanylglycine — Octahydroindole-2-carboxylic acid — Arginine.

62. (New) The method of Claim 61, wherein the animal is a human.

63. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

2,3,4,5,6-Pentafluorocinnamoyl — Lysine — Lysine — Arginine — Proline — Trans-4-hydroxyproline — Glycine — α-Cylcopentylglycine — Serine — D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid — α-Cyclopentylglycine.

64. (New) The method of Claim 63, wherein the animal is a human.

65. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

2,3,4,5,6-Pentafluorocinnamoyl — D-ε-Nicotinoyllysine — 4-(2-pyrazine carboxyl)ornithine — Proline — Trans-4-hydroxyproline — Glycine — α-2-Indanylglycine — Serine — D-α-2-Indanylglycine — Octahydroindole-2-carboxylic acid — Arginine.

66. (New) The method of Claim 65, wherein the animal is a human.

67. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

2,3,4,5,6-Pentafluorocinnamoyl — p-Fluorophenylalanine — Arginine.

68. (New) The method of Claim 67, wherein the animal is a human.

69. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

Dodecanedioyl — (D-Arginine — Pentafluororphenylalanine — Arginine)$_2$.

70. (New) The method of Claim 69, wherein the animal is a human.

71. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

2,3,4,5,6-Pentafluorocinnamoyl — O-2,6-Dichlorobenzyltyrosine — 4-Amino-2,2,6,6-tetramethylpiperidine.

72. (New) The method of Claim 71, wherein the animal is a human.

73. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

Dodecanedioyl — (D-Arginine — α-2-Indanylglycine — Arginine — 4-(Methylamino)-2,2,6,6-tetramethylpiperidine)$_2$.

74. (New) The method of Claim 73, wherein the animal is a human.

75. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, comprising the structure:

Ethylenediaminetetraacetyl — (O-2,6-Dichlorobenzyltyrosine — 4-(Methylamino)-2,2,6,6-tetramethylpiperidine)$_4$.

76. (New) The method of Claim 75, wherein the animal is a human.

77. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

(5-dimethylamino-1-naphthalenesulfonyl — D-Arginine — α-2-Indanylglycine — Argine)$_2$ — 1,10-Decanediamine.

78. (New) The method of Claim 77, wherein the animal is a human.

79. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

Dodecanedioyl — (D-Arginine — β-2Naphthylalanine — Arginine — 4-(methylamino)-2,2,6,6-tetramethylpiperidine)$_2$.

80. (New) The method of Claim 79, wherein the animal is a human.

81. (New) A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure:

Decanedioyl —

(— 4-Aminocinnamic acid — α-2-Indanylglycine — 4-amino-2,2,6,6-tetramethylpiperidine)$_1$

(— Lysine — D-Arginine — Arginine — Proline — Trans-4-hydroxyproline — Glycine — α-2-Indanylglycine — Serine — D-α-2-Indanylglycine — Octrahydroindole-2-carboxylic acid — Arginine)$_1$.

4 cont

82. (New) The method of Claim 81, wherein the animal is a human.

83. (New) A method to inhibit tumor growth in an animal in need of such inhibition, or induce apoptosis of cancer cells, comprising administering a compound, or a pharmaceutically acceptable salt thereof, of the structure: ACA1-(ε-Aminocaproic acid)$_2$-ACA2, wherein ACA1 and ACA2 are each independently a compound represented by a formula selected from the group consisting of:

2,3,4,5,6-Pentafluorocinnamoyl — D-Arginine — Arginine — Proline — Trans-4-hydroxyproline — Glycine — α-2-Indanylglycine — Serine — D-α-2-Indanylglycine — Octahydroindole-2-carboxylic acid — Arginine,

2,3,4,5,6-Pentafluorocinnamoyl — Lysine — Lysine — Arginine — Proline — Trans-4-hydroxyproline — Glycine — α-Cylcopentylglycine — Serine — D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid — α-Cylcopentylglycine,

2,3,4,5,6-Pentafluorocinnamoyl — D-ε-Nicotinoyllysine — 4-(2-pyrazine carboxyl)ornithine — Proline — Trans-4-hydroxyproline — Glycine — α-2-Indanylglycine — Serine — D-α-2-Indanylglycine — Octahydroindole-2-carboxylic acid — Arginine,

2,3,4,5,6-Pentafluorocinnamoyl — p-Fluorophenylalanine — Arginine, and

2,3,4,5,6-Pentafluorocinnamoyl — O-2,6-Dichlorobenzyltyrosine — 4-Amino-2,2,6,6-tetramethylpiperidine.